Logo image of TYRA

TYRA BIOSCIENCES INC (TYRA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TYRA - US90240B1061 - Common Stock

22.56 USD
+0.53 (+2.41%)
Last: 11/28/2025, 8:04:21 PM
22.4 USD
-0.16 (-0.71%)
After Hours: 11/28/2025, 8:04:21 PM
Fundamental Rating

3

Overall TYRA gets a fundamental rating of 3 out of 10. We evaluated TYRA against 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TYRA as it has an excellent financial health rating, but there are worries on the profitability. TYRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

TYRA had negative earnings in the past year.
TYRA had a negative operating cash flow in the past year.
TYRA had negative earnings in each of the past 5 years.
TYRA had a negative operating cash flow in each of the past 5 years.
TYRA Yearly Net Income VS EBIT VS OCF VS FCFTYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of TYRA (-32.92%) is better than 64.92% of its industry peers.
Looking at the Return On Equity, with a value of -35.03%, TYRA is in the better half of the industry, outperforming 73.92% of the companies in the same industry.
Industry RankSector Rank
ROA -32.92%
ROE -35.03%
ROIC N/A
ROA(3y)-25.06%
ROA(5y)-28.43%
ROE(3y)-26.84%
ROE(5y)-31.19%
ROIC(3y)N/A
ROIC(5y)N/A
TYRA Yearly ROA, ROE, ROICTYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

TYRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TYRA Yearly Profit, Operating, Gross MarginsTYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, TYRA has more shares outstanding
The number of shares outstanding for TYRA has been increased compared to 5 years ago.
There is no outstanding debt for TYRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TYRA Yearly Shares OutstandingTYRA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TYRA Yearly Total Debt VS Total AssetsTYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 34.89 indicates that TYRA is not in any danger for bankruptcy at the moment.
TYRA has a Altman-Z score of 34.89. This is amongst the best in the industry. TYRA outperforms 95.50% of its industry peers.
There is no outstanding debt for TYRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 34.89
ROIC/WACCN/A
WACCN/A
TYRA Yearly LT Debt VS Equity VS FCFTYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 21.94 indicates that TYRA has no problem at all paying its short term obligations.
With an excellent Current ratio value of 21.94, TYRA belongs to the best of the industry, outperforming 96.25% of the companies in the same industry.
TYRA has a Quick Ratio of 21.94. This indicates that TYRA is financially healthy and has no problem in meeting its short term obligations.
TYRA has a Quick ratio of 21.94. This is amongst the best in the industry. TYRA outperforms 96.25% of its industry peers.
Industry RankSector Rank
Current Ratio 21.94
Quick Ratio 21.94
TYRA Yearly Current Assets VS Current LiabilitesTYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

1

3. Growth

3.1 Past

The earnings per share for TYRA have decreased strongly by -16.15% in the last year.
EPS 1Y (TTM)-16.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.31% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-34.34%
EPS Next 2Y-21.25%
EPS Next 3Y-15.14%
EPS Next 5Y20.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TYRA Yearly Revenue VS EstimatesTYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M
TYRA Yearly EPS VS EstimatesTYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

0

4. Valuation

4.1 Price/Earnings Ratio

TYRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TYRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TYRA Price Earnings VS Forward Price EarningsTYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TYRA Per share dataTYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as TYRA's earnings are expected to decrease with -15.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.25%
EPS Next 3Y-15.14%

0

5. Dividend

5.1 Amount

No dividends for TYRA!.
Industry RankSector Rank
Dividend Yield N/A

TYRA BIOSCIENCES INC

NASDAQ:TYRA (11/28/2025, 8:04:21 PM)

After market: 22.4 -0.16 (-0.71%)

22.56

+0.53 (+2.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners104.99%
Inst Owner Change-11.2%
Ins Owners3.48%
Ins Owner Change-3.34%
Market Cap1.20B
Revenue(TTM)N/A
Net Income(TTM)-105.83M
Analysts88
Price Target32.13 (42.42%)
Short Float %9.3%
Short Ratio21.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.37%
Min EPS beat(2)5.89%
Max EPS beat(2)12.85%
EPS beat(4)3
Avg EPS beat(4)7.55%
Min EPS beat(4)-0.82%
Max EPS beat(4)12.85%
EPS beat(8)5
Avg EPS beat(8)4.21%
EPS beat(12)9
Avg EPS beat(12)9.47%
EPS beat(16)9
Avg EPS beat(16)-8.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.45%
EPS NY rev (1m)0%
EPS NY rev (3m)0.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.98
P/tB 3.98
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-2.22
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.63
OCFYN/A
SpS0
BVpS5.67
TBVpS5.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.92%
ROE -35.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.06%
ROA(5y)-28.43%
ROE(3y)-26.84%
ROE(5y)-31.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.94
Quick Ratio 21.94
Altman-Z 34.89
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.58%
Cap/Depr(5y)324.83%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.95%
EPS Next Y-34.34%
EPS Next 2Y-21.25%
EPS Next 3Y-15.14%
EPS Next 5Y20.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.55%
EBIT Next 3Y-21.25%
EBIT Next 5YN/A
FCF growth 1Y-97.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-98.41%
OCF growth 3YN/A
OCF growth 5YN/A

TYRA BIOSCIENCES INC / TYRA FAQ

What is the fundamental rating for TYRA stock?

ChartMill assigns a fundamental rating of 3 / 10 to TYRA.


What is the valuation status of TYRA BIOSCIENCES INC (TYRA) stock?

ChartMill assigns a valuation rating of 0 / 10 to TYRA BIOSCIENCES INC (TYRA). This can be considered as Overvalued.


How profitable is TYRA BIOSCIENCES INC (TYRA) stock?

TYRA BIOSCIENCES INC (TYRA) has a profitability rating of 1 / 10.


What is the financial health of TYRA BIOSCIENCES INC (TYRA) stock?

The financial health rating of TYRA BIOSCIENCES INC (TYRA) is 8 / 10.


What is the earnings growth outlook for TYRA BIOSCIENCES INC?

The Earnings per Share (EPS) of TYRA BIOSCIENCES INC (TYRA) is expected to decline by -34.34% in the next year.